You've got questions, we've got answers. Motley Full Money starts now.

I'm Chris Hill joining me today, Motley Full Senior Analyst, Osage Sharma. Thanks for

being here.

Chris, I appreciate you having me on. We've got a pair of blue chip stocks that are wrapping

up their fiscal years. We're going to start with Johnson and Johnson. Fourth quarter

profits fell 25% in part because demand for the company's COVID-19 vaccine fell. And

when you throw in the fact that inflation added to J&J's costs, you know, not a great

end of the fiscal year. And it leads into a very consequential year because later this

year, we're going to get the split. We're going to get the breakup of Johnson and Johnson.

But in terms of these results, was there anything in particular that stood out to you?

Chris, you know, to me, the story is how is Johnson and Johnson going to look going forward?

The impact of this year, in the way the fourth quarter ended, not great, but next year,

they're guiding to pretty decent results. I think the company is looking for some around

5% sales growth in the next year. Now, where is this going to come from? You know, the pharmaceutical

segment has been doing pretty well, even when you take out those COVID results and the combination

of the pharmaceutical division, plus the med tech division. These will be what Johnson

Johnson is left with after it spins off its consumer health segment. Those actually grew

at an adjusted level, pretty nicely last year, the pharmaceutical segment grew at around

a 7% rate, and the med tech segment grew at a rate of around 6%. So I think what they are

doing will help them as they don't have to worry as much about the more volatile. And

I would say slower growth consumer segment, even though you've got some great brands

that will be nestled up in this segment, which by the way is going to be called KenView,

...